Page 1

Almirall's solid core performance boosted by momentum ● ● ● ● almirall feel the science ● Good business performance with significant growth in Core EBITDA : Core Net Sales € 215.4 MM ( + 5 % year - on - year ) and Core EBITDA € 68.0MM ( + 46 % year - on - year ) Press Release Growth drivers momentum continues . Ilumetri® sales growing c . + 90 % year - on - year , KlisyriⓇ® launched successfully in the US in February 2021 and SeysaraⓇ modest rebound in line with the overall OAB market Barcelona , Spain May , 10th 2021 Gianfranco Nazzi joined as Almirall's new CEO on May 1st , 2021. His international experience and expertise in executing product launches will enable the company to deliver its global strategy and carry on the strategic roadmap Summary of results business Q1 growth drivers Innovative pipeline with significant value still to be unlocked : expected upcoming approvals of KlisyriⓇ and Wynzora® in Europe in Q2 2021 , and lebrikizumab phase 3 ongoing with headline readout expected in H2 2021 Based on the good start of the year - to - date performance , Almirall is reiterating its 2021 Guidance Almirall , S.A. ( ALM ) , the global biopharmaceutical company based in Barcelona , has announced its Q1 2021 financial results . Solid Core Q1 performance boosted by Growth Drivers and included some one - time items with positive impact on Net Sales for € 16 MM in Q1 2021 . Normalised net income was € 42.2 MM . Core Net Sales * reached € 215.4 MM , a 5 % year - on - year increase with positive contribution by Growth Drivers and one - offs ( includes divestment of a small product in Spain and licensing out income from another product with a combined positive impact on Net Sales of € 16 MM in Q1 2021 ) . Net Income reached € 29.8MM . Core EBITDA * increased 46 % year - on - year to € 68 MM with positive contribution by Growth Drivers and one - time items . Good Operating Cash Flow reached € 82.0MM .